The National Family Health Survey (NFHS-6) is far more than a public health report—it is one of India's most important strategic documents for healthcare leaders, investors, entrepreneurs and policymakers.

In this episode of Healthcare India, Dr. Vikram Venkateswaran analyses the latest NFHS-6 findings through the lens of healthcare strategy and explores how India's changing demographics will reshape healthcare delivery over the next decade.

Key topics include:

• Why India's ageing population will redefine healthcare demand
• The rapid rise of digital health readiness
• How health insurance is transforming healthcare economics
• Why healthcare must evolve from episodic treatment to continuous care
• The growing importance of AI, home healthcare and integrated care platforms
• Three bold predictions for Indian healthcare in 2035

If you are a healthcare CEO, founder, investor, clinician or policymaker, this episode provides strategic insights into where India's healthcare system is heading—and how organisations can prepare for the future.

In this episode, I speak with Akshay Verma, CEO & Founder of Fitpass, about the future of corporate wellness in India.

We explore how fitness behaviour is shifting across demographics and geographies, with surprising trends emerging in Tier 2 cities and among women who are adopting diverse workout formats.

The conversation also examines why corporate wellness programs are failing to create real impact, especially for India’s young workforce, and what needs to change.

We discuss:

• Behavioural vs. cultural vs infrastructure barriers to fitness
• India’s growing metabolic health crisis
• Data-backed insights on participation across age and gender
• Unexpected findings, including Agra’s rise as a highly active city

A sharp, data-driven conversation for leaders rethinking health, productivity, and workforce well-being.

The Manipal Health Enterprises IPO marks a shift in Indian healthcare—from expansion to efficiency.

In this episode, we break down what investors often miss:
This is not a turnaround or margin expansion play. Manipal is already operating at ~25–27% EBITDA margins and ~65–67% occupancy, with a ₹9,000 crore scale.

So what’s the real bet?

We explore:

Why this IPO is about sustaining excellence, not chasing growthThe true drivers of valuation: ARPOB, case mix, capital disciplineA realistic ₹45,000–₹60,000 crore valuation lensKey risks: doctor dependency, pricing pressure, integration complexity

If you’re looking beyond headlines to fundamentals, this episode will reframe the way you evaluate hospital IPOs.

This is not a bet on demand. It’s a bet on execution.